Kamada Ltd. - Ordinary Shares (KMDA): Price and Financial Metrics
Kamada Ltd. - Ordinary Shares (KMDA)
Today's Latest Price: $7.98 USD
Updated Jun 5 4:00pm
Add KMDA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
KMDA Stock Summary
- With a year-over-year growth in debt of 2,956.91%, Kamada Ltd's debt growth rate surpasses 98.99% of about US stocks.
- Over the past twelve months, KMDA has reported earnings growth of -325.17%, putting it ahead of just 5.2% of US stocks in our set.
- As for revenue growth, note that KMDA's revenue has grown 81.94% over the past 12 months; that beats the revenue growth of 93.12% of US companies in our set.
- Stocks that are quantitatively similar to KMDA, based on their financial statements, market capitalization, and price volatility, are UTSI, AWRE, OIIM, PGNX, and MOSY.
- Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.
KMDA Stock Price Chart More Charts
KMDA Price/Volume Stats
| Current price | $7.98 | 52-week high | $9.75 |
| Prev. close | $7.82 | 52-week low | $4.40 |
| Day low | $7.81 | Volume | 68,597 |
| Day high | $7.99 | Avg. volume | 89,654 |
| 50-day MA | $7.07 | Dividend yield | N/A |
| 200-day MA | $6.24 | Market Cap | 355.27M |
Kamada Ltd. - Ordinary Shares (KMDA) Company Bio
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.
KMDA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $7.98 | $2001.98 | 25566% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Kamada Ltd. To summarize, we found that Kamada Ltd ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 25692.17% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for KMDA, they are:
- As a business, KMDA is generating more cash flow than only 23.81% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately just 7.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- KMDA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.92% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 25063% |
| 1% | 25315% |
| 2% | 25566% |
| 3% | 25818% |
| 4% | 26070% |
| 5% | 26321% |
NVCR, VRTX, OMI, USNU, and CORT can be thought of as valuation peers to KMDA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...